PREVENTION OF GENITAL HERPES SIMPLEX INFECTION

在完成了十多年的生殖器抗病毒治疗工作后， 疱疹，我们转向疾病预防的研究。 我们完成了一个开放的 新的重组HSV-2糖蛋白D的2年I期评估 在24名成年人中接种明矾疫苗，其中一些人既往有或无HSV-1和/或2 感染 在0、1、2和12时接种30 ug或100 ug疫苗 个月，并与最小的局部或全身反应。 的 疫苗在细胞免疫应答中诱导良好的一抗 并显著增强了预先存在的体液和细胞反应。 我们 研究了以前未感染的受试者的抗体和T细胞， 表明抗体和细胞识别的gD 2表位 生殖器疱疹的症状有哪些？ 根据这些 我们招募了40例复发性生殖器疱疹患者， 进行安慰剂对照疫苗试验， 华盛顿大学。 目标是确定是否提高 免疫力导致复发频率降低。 该研究最近在 已完成，数据正在审查中。 我们也开始计划 在有效的新佐剂存在下使用gD 2和gB 2的进一步研究 MF59

Having completed over a decade of work on antiviral treatment of genital herpes, we turned to studies of disease prevention. We completed an open 2 year phase 1 assessment of a new recombinant HSV-2 glycoprotein D vaccine in alum in 24 adults, some with and without prior HSV-1 and/or 2 infection. Vaccinations of 30 ug or 100 ug were given at 0, 1, 2, and 12 months and were associated with minimal local or systemic reactions. The vaccine induced excellent primary antibody in cellular immune responses and augmented preexisting humoral and cellular responses signicantly. We studied antibody and T cells from previously uninfected subjects and showed that the gD2 epitopes that the antibody and cells recognize correspond to those in genital herpes patients. On the basis of these excellent responses we enrolled 40 patients with recurrent gential herpes into a placebo-controlled vaccine trial in collaboration with the University of Washington. The goal is to determine whether boosted immunity leads to less frequent recurrences. The study was recently completed and the data are being examined. We have also begun to plan for further studies using gD2 and gB2 in the presence of potent new aadjuvant MF59.